

MEF2C Antibody (S396)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP6285b

Specification

MEF2C Antibody (S396) - Product Information

Application Primary Accession Other Accession Reactivity Predicted Host Clonality Isotype Calculated MW Antigen Region WB,E <u>Q06413</u> <u>A4UTP7</u>, <u>A0A096MJY4</u> Human Pig, Rat Rabbit Polyclonal Rabbit IgG 51221 374-403

MEF2C Antibody (S396) - Additional Information

Gene ID 4208

Other Names Myocyte-specific enhancer factor 2C, MEF2C

Target/Specificity

This MEF2C antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 374-403 amino acids from human MEF2C.

Dilution WB~~1:1000 E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions MEF2C Antibody (S396) is for research use only and not for use in diagnostic or therapeutic procedures.

MEF2C Antibody (S396) - Protein Information

Name MEF2C (<u>HGNC:6996</u>)



Function Transcription activator which binds specifically to the MEF2 element present in the regulatory regions of many muscle-specific genes. Controls cardiac morphogenesis and myogenesis, and is also involved in vascular development. Enhances transcriptional activation mediated by SOX18. Plays an essential role in hippocampal-dependent learning and memory by suppressing the number of excitatory synapses and thus regulating basal and evoked synaptic transmission. Crucial for normal neuronal development, distribution, and electrical activity in the neocortex. Necessary for proper development of megakaryocytes and platelets and for bone marrow B-lymphopoiesis. Required for B-cell survival and proliferation in response to BCR stimulation, efficient IgG1 antibody responses to T-cell-dependent antigens and for normal induction of germinal center B-cells. May also be involved in neurogenesis and in the development of cortical architecture (By similarity). Isoforms that lack the repressor domain are more active than isoform 1.

Cellular Location Nucleus {ECO:0000250|UniProtKB:A0A096MJY4}. Cytoplasm, sarcoplasm {ECO:0000250|UniProtKB:A0A096MJY4}


Tissue Location Expressed in brain and skeletal muscle.

MEF2C Antibody (S396) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- <u>Western Blot</u>
- Blocking Peptides
- <u>Dot Blot</u>
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

MEF2C Antibody (S396) - Images



Western blot analysis of MEF2C (arrow) using rabbit polyclonal MEF2C Antibody (S396) (RB11048). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the MEF2C gene (Lane 2) (Origene Technologies).





All lanes : Anti-MEF2C Antibody (S396) at 1:1000 dilution Lane 1: Jurkat whole cell lysate Lane 2: K562 whole cell lysate Lysates/proteins at 20 μ g per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 51 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

MEF2C Antibody (S396) - Background

MEF2C is a transcription activator which binds specifically to the MEF2 element present in the regulatory regions of many muscle-specific genes. This protein controls cardiac morphogenesis and myogenesis, and is also involved in vascular development. It may also be involved in neurogenesis and in the development of cortical architecture.

MEF2C Antibody (S396) - References

Konig, S., et al., J. Biol. Chem. 279(27):28187-28196 (2004). Maeda, T., et al., J. Biol. Chem. 277(50):48889-48898 (2002). Maeda, T., et al., Biochem. Biophys. Res. Commun. 294(4):791-797 (2002). Janson, C.G., et al., Brain Res. Mol. Brain Res. 97(1):70-82 (2001). Krainc, D., et al., Genomics 29(3):809-811 (1995).